Research progress of adoptive cell therapy in malignant glioma

Abstract

Malignant glioma is the most common malignant tumor of central nervous system (CNS). Surgery is the main treatment method, supplemented by radiation and chemotherapy. But the problems of too much trauma, easy recurrence and poor prognosis cannot be avoided. Because of strong anti-tumor specificity, mild adverse reaction and long-term memory etc, immune therapy may be the best auxiliary treatment, and even can replace the surgical treatment. This article focused on the role of engineering cells, including lymphokine-activated killer cell (LAK), natural killer cell (NK), γδ T cell, tumor infiltrating lymphocyte cell (TIL), cytotoxic T lymphocyte cell (CTL) and CD4⁺ T cell, in the process of treating malignant glioma by adoptive cell therapy (ACT) and reviewed the characteristics, advantage and disadvantages, research trends and progress of these cells.

DOI: 10.3969/j.issn.1672-6731.2016.02.008